Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSTP.L Regulatory News (STP)

  • There is currently no data for STP

Director/PDMR Shareholding

22 Jun 2018 11:00

RNS Number : 2301S
Stenprop Limited
22 June 2018
 

 

STENPROP LIMITED

(Registered in Guernsey)

(Registration number 64865)

LSE share code: STP JSE share code: STP

ISIN: GG00BFWMR296

("Stenprop" or the "Company")

 

 

DEALINGS IN SECURITIES BY A DIRECTOR OF A MAJOR SUBSIDIARY OF THE COMPANY AND ISSUE OF NEW SHARES

 

 

22 June 2018

 

Shareholders are advised of the following information relating to the acceptance of market value options awarded on 7 June 2018 under the Stenprop Limited Long Term Incentive Plan ("Long Term Incentive Plan"). The market value options will vest in three tranches on 31 March 2019, 31 March 2020 and 31 March 2021 and once fully vested will result in the issue of 95 816 shares subject to the payment of the exercise price of £1.10 per share, for a deemed value of £105 397.60.

 

Name of director:

Name of subsidiary companies:

Nicolaas Marais

Stenprop (UK) Limited and Stenprop (Germany) Limited

Transaction date:

7 June 2018

Class of securities:

Market value options

Number of securities:

95 816

Nature of transaction:

Nature and extent of director's interest:

Clearance to deal received:

Off-market acceptance of market value options in terms of the Long Term Incentive Plan

Direct beneficial

Yes

 

Shareholders are further advised of the following information relating to the acceptance of nil cost options awarded on 7 June 2018 under the Stenprop Limited Amended Deferred Share Bonus Plan ("Deferred Bonus Plan"). One third of these nil cost options vested immediately, with the second third vesting on 31 March 2019 and the last third vesting on 31 March 2020. Once fully vested, they will result in the issue of 18 363 shares.

 

Name of director:

Name of subsidiary companies:

Nicolaas Marais

Stenprop (UK) Limited and Stenprop (Germany) Limited

Transaction date:

7 June 2018

Class of securities:

Nil cost options

Number of securities:

18 363

Nature of transaction:

Nature and extent of director's interest:

Clearance to deal received:

Off-market acceptance of nil cost options in terms of the Deferred Bonus Plan

Direct beneficial

Yes

 

Shareholders are further advised of the exercise of nil cost options awarded under the Deferred Bonus Plan, comprising 6 121 nil cost options granted on 7 June 2018, which vested immediately, 3 675 options awarded on 8 June 2017 which vested on31 March 2018 and 5 283 options awarded on 9 June 2016 which vested on 31 March 2018, which will result in the issuance of 15 079 shares, in each case at a deemed value of £1.185 per share.

 

Name of director:

Name of subsidiary companies:

Nicolaas Marais

Stenprop (UK) Limited and Stenprop (Germany) Limited

Transaction date:

20 June 2018

Class of securities:

Nil cost options

Number of securities:

15 079

Deemed total value:

Nature of transaction:

Nature and extent of director's interest:

Clearance to deal received:

£17,868.61

Off-market exercise of nil cost options in terms of the Deferred Bonus Plan

Direct beneficial

Yes

 

Following the transaction, Nicolaas Marais' beneficial interest in the Company is 295 679 shares, representing approximately 0.10% of the issued capital of the Company.

 

ISSUE OF NEW SHARES

 

Application has been made for 50 819 new ordinary shares to be admitted to the Specialist Fund Segment of the London Stock Exchange and to the Main Board of the JSE. This application includes the above 15 079 vested options exercised by Nicolaas Marais and an additional 35 740 ordinary shares in relation to the exercise of additional nil cost options by an employee of the Stenprop group in terms of the Deferred Bonus Plan. It is expected that admission will take place at 8.00 am on 26 June 2018.

 

 

 

Enquiries:

 

Stenprop Limited

Paul ArensonPatsy WatsonJulian Carey

+44(0)20 7079 6600

 

Numis Securities Limited (Financial Adviser)

Hugh JonathanVicki Paine

+44(0)20 7260 1000

 

Tavistock (PR adviser)

James Whitmore

James Verstringhe

Kirsty Allan

+44(0)20 7920 3150

 

JSE Sponsor

Java Capital Trustees and Sponsors Proprietary Limited

+ 27 (0) 11 722 3050

 

About Stenprop

Stenprop is a Guernsey-registered UK REIT. The objective of the Company is to deliver sustainable growing income to its investors. Stenprop's investment policy is to invest in a diversified portfolio of UK multi-let industrial (MLI) properties with the strategic goal of becoming the leading MLI business in the UK. For further information, go to www.stenprop.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFKBDPOBKKFAB
Date   Source Headline
16th Nov 20207:00 amRNSAcquisition of two multi-let industrial estates
4th Nov 20207:00 amRNSChanges To The Board Of Directors
23rd Oct 20207:00 amRNSMLI Trading Update
2nd Oct 202011:00 amRNSTransaction in Own Shares
1st Oct 202011:00 amRNSTransaction in Own Shares
1st Oct 20207:00 amRNSCompletion Of Disposal Of Retail Park In Berlin
30th Sep 202011:00 amRNSTransaction in Own Shares
23rd Sep 202011:00 amRNSDealings By Associate Of A Director Of the Company
22nd Sep 20207:00 amRNSAcquisitions take MLI portfolio past 5mn sq ft
17th Sep 202012:00 pmRNSResult of AGM And Change Of External Auditor
11th Sep 20201:00 pmRNSCHANGE IN NUMBER OF VOTING RIGHTS
10th Sep 202011:00 amRNSTransaction in Own Shares
9th Sep 20203:30 pmRNSDirector/PDMR Shareholding
3rd Sep 20202:00 pmRNSDirector/PDMR Shareholding
21st Aug 202011:00 amRNSTransaction in Own Shares
20th Aug 202011:00 amRNSTransaction in Own Shares
19th Aug 202011:00 amRNSTransaction in Own Shares
13th Aug 20209:00 amRNSResult Of Election For Cash Or Scrip Dividend
6th Aug 202011:00 amRNSDirector/PDMR Shareholding
6th Aug 20207:00 amRNSAcquisition of Glasgow multi-let industrial estate
5th Aug 202011:00 amRNSDirector/PDMR Shareholding
31st Jul 20202:00 pmRNSPosting Of Notice Of Annual General Meeting
24th Jul 20207:00 amRNSTrading And Rent Collection Update
22nd Jul 20207:00 amRNSAcquisition Of Bowthorpe Park For £19.6M
17th Jul 202011:00 amRNSDealings By A Director Of The Company
16th Jul 20207:00 amRNSDisposal of Berlin Retail Park for EUR27.0M
14th Jul 20209:00 amRNSFinalisation Announcement In Respect Of Election
7th Jul 20207:00 amRNSStenprop Acquires 43,500 sqft Multi Let Industrial
3rd Jul 20202:00 pmRNSScrip Dividend Circular
3rd Jul 202011:00 amRNSDirector/PDMR Shareholding
29th Jun 20203:00 pmRNSPerson Discharging Managerial Responsibility
25th Jun 20202:00 pmRNSNo Change Statement & Publication Of Annual Report
17th Jun 202011:00 amRNSDEALINGS IN SECURITIES BY DIRECTORS AND SECRETARY
12th Jun 20207:00 amRNSSummarised results for year ended 31 March 2020
12th Jun 20207:00 amRNSPreliminary results for year ended 31 March 2020
10th Jun 20203:00 pmRNSChange to the board of directors
29th May 20207:00 amRNSNotice of Annual Results - 31 March 2020
5th May 20207:00 amRNSCOVID-19 and MLI portfolio updates
21st Apr 20207:00 amRNSCOVID-19 second update
3rd Apr 20202:00 pmRNSDirector/PDMR Shareholding
26th Mar 20207:00 amRNSCovid-19 update
20th Mar 20204:38 pmRNSPrice Monitoring Extension
13th Mar 20202:00 pmRNSDirector/PDMR Shareholding
11th Mar 20202:00 pmRNSDirector/PDMR Shareholding
9th Mar 20209:00 amRNSTransaction in Own Shares
5th Mar 20207:00 amRNSCOMPLETION OF DISPOSAL OF THE BLEICHENHOF PROPERTY
28th Feb 20202:30 pmRNSTransaction in Own Shares
25th Feb 20208:00 amRNSDirector/PDMR Shareholding
19th Feb 20203:04 pmRNSResult of General Meeting
13th Feb 202010:00 amRNSResult of election for cash or scrip dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.